Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Anticipating an April 15 user fee date for oral ocreotide for acromegaly, Chiasma thinks its platform technology to make peptides orally available can offer substantial opportunities for therapeutic optionality.
You may also be interested in...
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.
The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses
ChatGPT’s ability to perform sophisticated analysis and writing tasks has taken the world by storm, and now one developer has launched its own AI aimed at revolutionizing pharma’s business intelligence functions.
The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge
With a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique spectrum of challenges in driving low carbon health care. Nevertheless, it has set the bar high in environmental sustainability goals, and is pressing suppliers to follow its lead.